← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV25행 · 1개 프로그램
OverviewMoAPK/PDToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePreclinical
Proteasome Inhibitor (Proteasome Inhibitor)
Sung-Soo Park·FRα
57 trials·t½ 5 h
Overview
Program
Proteasome Inhibitor
Overview
Company
Sung-Soo Park
Overview
Modality
CGT
Overview
Target
FRα
Overview
Indication
Multiple Myeloma, Relapsed; Multiple Myeloma (MM)
Overview
Phase
PRECLINICAL
Overview
Status
RECRUITING
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
MoA
Mechanism
in myofibroblasts remain undefined
PK/PD
Half-life
5 h
PK/PD
Species
Mouse
PK/PD
Animal (cat.)
Mouse, In vitro
PK/PD
Experiment
PK
Toxicology
Species
Mouse
Toxicology
Animal (cat.)
Mouse, In vitro
Toxicology
Major finding
thrombocytopenia, endothelial injury, and macrophage activation, ultimately amplifying systemic
Clinical
Safety signal
thrombocytopenia, endothelial injury, and macrophage activation, ultimately amplifying systemic
Clinical
Selected reported efficacy
ORR 88%
Clinical
Reported ORR
88%
Clinical
Result source
ClinicalTrials.gov NCT01217957
Clinical
Program phase
PRECLINICAL
Clinical
Trial ref
NCT01217957